The report presents an in-depth assessment of the Middle East & Africa Human Insulin including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Middle East & Africa Human Insulin investments from 2019 till 2024.
The Middle East & Africa human insulin market has potential to grow, and it is expected to grow at approximately 4% CAGR during the forecast period (2019-2024).
The Middle East & Africa insulin market is dominated by Novo Nordisk, Sanofi and Eli Lilly. However, there are many local players like Julphar, Sedico, and Exir, who hold a significant market share.
Click the link to get a free Sample Copy of the Report:
Scope of the Report
The Middle East & Africa human insulin market is segmented by Product Type (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), and by Region, which covers Saudi Arabia, Iran, Egypt, South Africa, Oman & the Rest of Middle East & Africa.
Key Market Trends
Increasing Diabetes Prevalence is Expected to Boost the Market in the Forecast Period
– The prevalence of Type 2 Diabetes mellitus (T2DM) has increased dramatically during the last two decades – a fact driven by the increased prevalence of obesity, the primary risk factor for T2DM. Many reports and surveys documented a drastic increase in the diabetic population based on lifestyle habits. High growth in urbanization has worsened physical inactivity, and in turn, making diabetes is a major health concern.
– The R&D in the insulin segments are growing year-on-year, where scientists are trying to bring out the best molecule for patients use by curbing the maximum extent of side effects, and by increasing their efficiency..
Inquire for Discount:
Biosimilar Insulins hold a Significant Market Share
– Biosimilar insulin is highly popular in the Middle East & Africa region because of its low cost as compared to branded insulins.
– The Middle Eastern & African countries have substantial economic diversity. The per-capita expenditure on diabetes in the region is low, although some countries in the region have managed to modify their healthcare expenditure to include biologic and biosimilar therapies.
– Biosimilars have grown with a high CAGR of 13% in the historical period because of consistent efforts by local manufacturers to capture the highly consolidated market.
Browse the Full report description and TOC at:
What are the market factors that are explained in the report?
–Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.
–Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.
–Analytical Tools: Middle East & Africa Human Insulin Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter’s five forces analysis, feasibility study, and investment return analysis have been used to analyzed the growth of the key players operating in the market.
The research includes historic data from 2014 to 2019 and forecasts until 2025 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.
Media Contact Us:
Irfan Tamboli (Head of Sales) – Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
firstname.lastname@example.org | email@example.com